Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT

Movement Disorders

Volumn 19, Issue 10, 2004, Pages 1196-1202

  Sommer, Ulrike ^a   Hummel, Thomas ^a   Cormann, Katja ^a   Mueller, Antje ^a   Frasnelli, Johannes ^a   Kropp, Joachim ^a   Reichmann, Heinz ^a  

^a UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

Author keywords

Neurodegeneration; Olfaction; Predictor; Smell; Transcranial sonography

Indexed keywords

IODINE 123;

ADULT; AGED; ANOSMIA; ARTICLE; BASAL GANGLION; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DIAGNOSTIC IMAGING; DOPAMINERGIC NERVE CELL; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SYMPTOMATOLOGY;

ADULT; AGED; ECHOENCEPHALOGRAPHY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OLFACTION DISORDERS; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 4043078792     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20141     Document Type: Article

References (53)

1. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chron Dis 1975;28:493-497.
2. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-946.
3. Doty RL, Deems D, Steller S. Olfactory dysfunction in Parkinson's disease: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
4. Sobel N, Thomason ME, Stappen I, et al. An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:4154-4159.
5. Barz S, Hummel T, Pauli E, Majer M, Lang CJ, Kobal G. Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson's disease. Neurology 1997;49:1424-1431.
6. Hawkes CH, Shephard BC. Olfactory evoked responses and identification tests in neurological disease. Ann N Y Acad Sci 1998; 855:608-615.
7. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998; 55:84-90.
8. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? Q J Med 1999;92:473-480.
9. Hawkes CH. Olfaction in neurodegenerative disease. Mov Disord 2003;18:364-372.
10. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
11. Roth J, Radil T, Ruzicka E, Jech R, Tichy J. Apomorphine does not influence olfactory thresholds in Parkinson's disease. Funct Neurol 1998;13:99-103.
12. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994;44:266-268.
13. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41-46.
14. Hummel T. Olfactory evoked potentials as a tool to measure progression of Parkinson's Disease. In: Chase T, Bedard P, editors. Focus on medicine. Vol. 14. New developments in the drug therapy of Parkinson's disease. Oxford: Blackwell Science; 1999. p 47-53.
15. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50: 34-41.
16. Tissingh G, Bergmans P, Booij J, et al. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT. J Neurol 1998;245:14-20.
17. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
18. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
19. Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002;109:805-811.
20. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976;38:277-301.
21. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991;41:8-13.
22. Horstink MW, Morrish PK. Preclinical diagnosis of Parkinson's disease. Adv Neurol 1999;80:327-333.
23. Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson's disease. J Neurol 2000;247:II103-II109.
24. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
25. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59:999-1005.
26. Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002;109: 191-196.
27. Berg D, Supprian T, Hofmann E, et al. Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 1999;246:1186-1193.
28. Cullen MM, Leopold DA. Disorders of smell and taste. Med Clin North Am 1999;83:57-74.
29. Welge-Luessen A, Temmel A, Quint C, Moll B, Wolf S, Hummel T. Olfactory function in patients with olfactory groove meningioma. J Neurol Neurosurg Psychiatry 2001;70:218-221.
30. Temmel AF, Quint C, Schickinger-Fischer B, Klimek L, Stoller E, Hummel T. Characteristics of olfactory disorders in relation to major causes of olfactory loss. Arch Otolaryngol Head Neck Surg 2002;128:635-641.
31. Hummel T, Knecht M. Smell and taste disorders. In: Calhoun KH, editor. Expert guide to otolaryngology. Philadelphia, PA: American College of Physicians; 2001. p 650-664.
32. Seiden AM, Duncan HJ. The diagnosis of a conductive olfactory loss. Laryngoscope 2001;111:9-14.
33. Jafek BW, Moran DT, Eller PM, Rowley JC III, Jafek TB. Steroid-dependent anosmia. Arch Otolaryngol Head Neck Surg 1987;113: 547-549.
34. Hastings L, Miller ML. Olfactory loss to toxic exposure. In: Seiden AM, editor. Taste and smell disorders. New York: Thieme; 1997. p 88-106.
35. Hummel T, Sekinger B, Wolf S, Pauli E, Kobal G. 'Sniffin' Sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997;22:39-52.
36. Kobal G, Klimek L, Wolfensberger M, et al. Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol 2000;257:205-211.
37. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002;17:867-876.
38. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;NS25:638-613.
39. Tatsch K, et al. Functional imaging of the dopaminergic system with SPECT. KNP Project 5. Kompetenznetz Parkinson [available online at http://www.kompetenznetz-parkinson.de/english/html/3/3c/ knp_tp5.pdf]. Posted 29 November 2001.
40. Shinotoh H, Uchida Y, Ito H, Harrori T. Relationship between striatal [123I]β-CIT binding and four major clinical signs in Parkinson's disease. Ann Nucl Med 2000;14:199-203.
41. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
42. Koller WC. When does Parkinson's disease begin? Neurology 1992;42:27-31; discussion 41-48.
43. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS, Lees AJ. Diffuse Lewy body disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psychiatry 1991;54:159-161.
44. Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. Lancet 1994;344:1503.
45. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extra nigral pathology in Parkinson's disease. J Neural Transm Suppl 1995;46:15-31.
46. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 1989;52:515-520.
47. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
48. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-1765.
49. Booij J, Habraken J, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-1884.
50. Eising EG, Muller TT, Zander C, et al. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]β-CIT) in untreated patients with suspicion of Parkinson disease. J Investig Med 1997;45:448-452.
51. Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001;39:101-108.
52. Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov Disord 1997;12:885-897.
53. Schwarz J, Linke R, Kerner M, et al. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 2000;57:205-208.